NeoGenomics, Inc. revised earnings guidance for the fiscal year 2023. For the year, the company expects consolidated revenue to be in the range of $565 million to $575 million against previous guidance range of $555 million to $565 million. Net loss to be in the range of $107 million to $100 million against previous guidance range of $116 million to $108 million.